Loading clinical trials...

Assess Performance Attributes and Acceptability of Non-medicated Intravaginal Rings Among Sexually Active Women in Atlanta, GA | Clinical Trials | Clareo Health

RECRUITINGEARLY_PHASE1

Assess Performance Attributes and Acceptability of Non-medicated Intravaginal Rings Among Sexually Active Women in Atlanta, GA

A Randomized Open Label Crossover Trial to Assess Performance Attributes and Acceptability of Non-medicated Intravaginal Rings Among Sexually Active Women in Atlanta, GA

NCT07039591•Population Council

View on ClinicalTrials.gov

Summary

A randomized open label crossover trial to assess performance attributes and acceptability of non-medicated intravaginal rings among sexually active women in Atlanta, GA

Eligibility

Age

18 - 49 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•1\. Cisgender female aged 18-49 years old, inclusive, at screening based on self-report.
•2\. Sexually active, defined as having penile-vaginal sex at least once a week, on average, over the past three months with the same male partner, and intends to continue having sexual intercourse at the current frequency for at least three months.
•3\. Healthy based on medical history, physical exam (including pelvic exam with visual inspection) at screening.
•4\. Using effective non-vaginal method of contraception (oral contraception, injectable, patch, IUD, sterilization, male condoms) 5. Competent to provide written informed consent based on Investigator's assessment.
•6\. Agrees to not participate in any other clinical research involving investigational or marketed products for the duration of this trial.

Exclusion Criteria

•1\. Known or suspected allergy to silicone or EVA, as reported by participant. 2. Positive pregnancy test at screening or enrollment based on urine hCG test. 3. Positive for HIV at screening based on rapid test per site SOPs. 4. Presence of any clinically significant genital epithelial findings (e.g. abrasions, ulcerations, lacerations, or vesicles) at screening.
•5\. Positive chlamydia, gonorrhea, or trichomoniasis test at screening. 6. Symptomatic vulvovaginal candidiasis, bacterial vaginosis (BV), or urinary tract infection (UTI) at screening. (Participants who are symptomatic at initial screening will be referred for testing and treatment and may be reconsidered for eligibility after completing treatment and/or if no longer symptomatic).
•7\. Presence of genital abnormalities on visual exam with speculum that would contraindicate IVR use.
•8\. History of significant uterine or vaginal prolapse, or urethral obstruction. 9. Unexplained vaginal bleeding per self-report within the last three months. 10. Currently breastfeeding per self-report. 11. Partial or complete hysterectomy per self-report. 12. History of gynecological surgery in the six months prior to screening per self-report.
•13\. Within six weeks post abortion or six months postpartum, per self-report. 14. Using vaginal contraception (diaphragm, female condom, spermicide, IVR). 15. Known current drug abuse, including illicit drugs, or alcohol abuse. 16. Any other condition the clinician feels would jeopardize the health and wellbeing of the participant after assessing the participant's potential eligibility for the study.
•17\. Unable to comply with study requirements, including but not limited to, attending all study visits and using the IVRs as directed.
•18\. Participation in any other clinical research trial involving investigational or marketed products currently or within one month of participation prior to screening, including any trial of a spermicide, microbicide and/or drug.

Locations (1)

Emory University

Atlanta, Georgia, United States

Key Dates

Start Date

August 8, 2025

Primary Completion Date

April 30, 2026

Completion Date

October 30, 2026

Last Updated

September 5, 2025

Enrollment

ESTIMATED participants

Conditions

Contraceptive Usage

Interventions

Pro-type IVR

DEVICE

Contacts

Irene Bruce

CONTACT

16468215100 ibruce@popcouncil.org

Telemedicine Contraceptive Counselling (TECC) Versus Standard Care

NCT06682065

Contraceptive UsageTelemedicine

View study

RECRUITINGPHASE4

Disparities in Emergency Contraceptive Metabolism Dictate Efficacy

NCT05674513

Contraceptive Usage

View study

ENROLLING_BY_INVITATIONNA

A Web-Based Tool to Help People With Health Conditions Make Contraceptive Decisions

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Assess Performance Attributes and Acceptability of Non-medicated Intravaginal Rings Among Sexually Active Women in Atlanta, GA

Inclusion Criteria

Exclusion Criteria

Telemedicine Contraceptive Counselling (TECC) Versus Standard Care

Disparities in Emergency Contraceptive Metabolism Dictate Efficacy

A Web-Based Tool to Help People With Health Conditions Make Contraceptive Decisions

The Over The Counter Pill National Study

Contraception Navigator Program

Increase First-time Mothers' Use of Postpartum Family Planning in Bangladesh: The Connect Project